Kastle Theraps Llc patent expiration

1. Kynamro patent expiration

KYNAMRO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7511131 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6222025 KASTLE THERAPS LLC Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
Mar, 2015

(9 years ago)

US5914396 KASTLE THERAPS LLC 2'-O-modified nucleosides and phosphoramidites
Jun, 2016

(8 years ago)

US6451991 KASTLE THERAPS LLC Sugar-modified gapped oligonucleotides
Feb, 2017

(7 years ago)

US6166197 KASTLE THERAPS LLC Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
Dec, 2017

(6 years ago)

US7407943 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Aug, 2021

(2 years ago)

US7015315 KASTLE THERAPS LLC Gapped oligonucleotides
Mar, 2023

(1 year, 3 months ago)

US7101993 KASTLE THERAPS LLC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(10 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 29, 2018
Orphan Drug Exclusivity(ODE-41) Jan 29, 2020
Orphan Drug Exclusivity(ODE) Jan 29, 2020

Drugs and Companies using MIPOMERSEN SODIUM ingredient

NCE-1 date: 29 January, 2017

Market Authorisation Date: 29 January, 2013

Treatment: Adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with h...

Dosage: SOLUTION

More Information on Dosage

KYNAMRO family patents

Family Patents